New beta-blocker trialled

Article

Othera Pharmaceuticals' topical beta blocker, OT-730, indicated for the reduction of intraocular pressure (IOP) in subjects with ocular hypertension and open-angle glaucoma, has begun a Phase I/II clinical trial for safety and efficacy.

Othera Pharmaceuticals' topical beta blocker, OT-730, indicated for the reduction of intraocular pressure (IOP) in subjects with ocular hypertension and open-angle glaucoma, has begun a Phase I/II clinical trial for safety and efficacy.

The randomized multicentre study, in which the investigators will be masked, will segregate subjects into treatment groups receiving either 0.75% OT-730, 0.5% timolol maleate or placebo. Due to its unique chemical make-up, Othera is confident that OT-730 will not produce the systemic side effects commonly associated with beta-blockers. Indeed, during preclinical studies, OT-730 demonstrated a safety and IOP-lowering efficacy profile which was superior to that of timolol maleate.

Othera is also currently running a Phase II trial for OT-551, a small molecule to inhibit oxidative stress and inflammation due to disease, for dry age-related macular degeneration.

Related Videos
A screenshot of Dr Filomena Ribeiro, president of the ESCRS
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.